ArticleAdvances in therapy2023

Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population.

Jeffrey S Berger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.